Participants wi th renal insufficiency should be assessed as to whether or not they should receive contrast and, if so, what type and dose of contrast are appropriate. MRI contrast should not be given to participants with severe renal insufficiency (eg, estimated GFR < 30 mL/min/1.73 m2) because of increased risk of nephrogenic systemic fibrosis in this participant population. In these participants, alternative imaging tests or MRI without gadolinium should be considered. In addi tion, participants should be excluded from MRI if they have uncontrollable claustrophobia, metallic implants, pacemakers, and so on. The ultimate decision to perform MRI in an individual participant in this study rests with the site radiologist, the investigator, and the standard set by the local Ethics Committee (EC). 7.6.2 Permitted Therapy Participants are permitted the use of the following treatments: •Topical, ocular, intra-articular, intra-nasal, and inhalational corticosteroids (with minimal systemic absorption). •Adrenal replacement steroid doses ≤10 mg daily prednisone equivalent. •A brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen). •Bisphosphonates and RANKL directed-thera pies for bone metastases are permitted. Systemic immunosuppressive agents and the use of systemic corticosteroids are permitted in the context of treating AEs. Participants receiving c orticosteroids for treatment of drug-related AEs must be receiving < 10 mg/day prednisone equivalent for < 5 days up to 7 days prior to re-initiation of study treatment. Participants may c ontinue to receive hormone replacement therapy. 7.6.3 Palliative Local Therapy Palliative and supportive care for disease-related symptoms may be offered to all participants on the study after the DLT evaluation period. Limited radiation therapy or surgery to control isolated lesions is permitted for participants who have investigator-assessed clinical benefit following consultation with the BMS Medical Monitor/Study Director (or designee). Participants should not receive study tr eatment during radiation, as the potential for overlapping toxicities with radiotherapy and BMS-986226 or BMS-986226 in combination with nivolumab or ipilimumab is currently not known. Anecdotal data suggest that radiotherapy administered to participants while receiving nivo lumab or ip ilimumab therapy is tolera ble. However, because concurrent radiotherapy and immunotherapies in cancer have not been formally evaluated, in cases where palliative radiotherapy is required for a tumor lesion, BMS-986226 alone or in combination with nivolumab or ipilimumab should be withheld for at least 1 week before, during, and 1 week Revised Protocol No.: 04 Date: 31-May-2019 92 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS after radiation. Participants should be closely monitored for any potential toxicity during and after receiving radiotherapy, and AEs related to radiotherapy should resolve to Grade 1 prior to resuming study treatment.